Pietro Fiore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Pietro Fiore has a total of 247 co-authors. Here are the top co-authors by number of shared publications:
- Francesco Panza
“Cesare Frugoni” Internal and Geriatric Medicine and Memory Unit, Department of Interdisciplinary Medicine, University of Bari Aldo Moro, 70124 Bari, Italy
27 shared publications - Vincenza Frisardi
Geriatric and Neuro Rehabilitation Department, Clinical Center for Nutrition in the Elderly, AUSL-IRCCS Reggio Emilia, Giovanni Amendola Street, 42122 Reggio Emilia, Italy
16 shared publications Maurizio Ranieri
Physical Medicine and Rehabilitation Section, "OORR" Hospital, University of Foggia, Foggia, Italy
15 shared publications- Marisa Megna
Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari Aldo Moro, G. Cesare Place 11, 70125 Bari, Italy
14 shared publications - Andrea Santamato
Department of Physical Medicine and Rehabilitation, University of Foggia, Foggia, Italy
12 shared publications Andrea Santamato
Department of Physical Medicine and Rehabilitation, "OORR Hospital", University of Foggia, Foggia, Italy
9 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 115
Effects of neurofeedback and biofeedback on cognitive, affective, and motor outcomes in adults with multiple sclerosis: a systematic review
- 26 August 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 115
Open AccessEffects of neurofeedback and biofeedback on cognitive, affective, and motor outcomes in adults with multiple sclerosis: a systematic review
- Open Access
- 29 May 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (4) , 1-2
Correction: “Not That I’ve Become Exceptional, But I’m Able to Make Myself Understood Better”: Impact of Speech and Language Therapy on Everyday Communication in People with Primary Progressive Aphasia and Their Carers
- 29 May 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (4) , 1-2
Open AccessCorrection: “Not That I’ve Become Exceptional, But I’m Able to Make Myself Understood Better”: Impact of Speech and Language Therapy on Everyday Communication in People with Primary Progressive Aphasia and Their Carers
- Open Access
- 6 February 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (2) , 717-731
“Not That I’ve Become Exceptional, But I’m Able to Make Myself Understood Better”: Impact of Speech and Language Therapy on Everyday Communication in People with Primary Progressive Aphasia and Their Carers
Introduction Primary progressive aphasia (PPA) is a neurodegenerative syndrome characterized by progressive speech and language impairments that impact communication, independence, and psychosocial well-being. People with PPA (PwPPA) and their carers face communication difficulties that lead to social withdrawal. Speech and language therapy (SLT) offers non-pharmacological strategies to support communication, yet evidence regarding its perceived impact on daily life remains limited. This study explored the experiences of PwPPA and their carers following SLT, focusing on perceived changes in communication abilities, confidence, and psychosocial well-being. Methods PwPPA participated in a 5-week, tailored telerehabilitation program (Lexical Retrieval Cascade Treatment for logopenic PPA/semantic PPA; Video-Implemented Script Training for nonfluent/agrammatic PPA). Post-treatment questionnaires were developed to collect the opinions of PwPPA and their carers regarding the SLT. The questionnaires included 22 closed-ended Likert-scale items and two open-ended questions for each group. Quantitative data were analyzed for frequency and consistency between PwPPA and carers, while qualitative responses underwent reflexive thematic analysis. Twenty-five PwPPA and 24 carers completed the questionnaires. Results Quantitative findings showed consistent perceptions between PwPPA and carers, with approximately 30% reporting improvements in communication confidence, speaking ability, and stress. Thematic analysis revealed four shared themes: reduction in negative emotions/increased self-efficacy, proactivity, acquisition of compensatory strategies, and the importance of the treatment setting and patient–clinician relationship. Additional themes included enhanced communicative effectiveness for PwPPA and increased awareness and improved interpersonal relationships for carers. Participants emphasized the benefits of individualized, supportive therapy delivered in a comfortable environment, including via telerehabilitation. Conclusion Our study highlights the positive influence of SLT on both communication and psychosocial outcomes in PwPPA and their carers. Integrating subjective experiences with quantitative measures underscores the importance of person-centered, holistic interventions that address linguistic, emotional, and social dimensions, supporting everyday communication and quality of life.
- 6 February 2026
- Published by Springer Nature in Neurology and Therapy
- Vol. 15 (2) , 717-731
Open Access“Not That I’ve Become Exceptional, But I’m Able to Make Myself Understood Better”: Impact of Speech and Language Therapy on Everyday Communication in People with Primary Progressive Aphasia and Their Carers
Introduction Primary progressive aphasia (PPA) is a neurodegenerative syndrome characterized by progressive speech and language impairments that impact communication, independence, and psychosocial well-being. People with PPA (PwPPA) and their carers face communication difficulties that lead to social withdrawal. Speech and language therapy (SLT) offers non-pharmacological strategies to support communication, yet evidence regarding its perceived impact on daily life remains limited. This study explored the experiences of PwPPA and their carers following SLT, focusing on perceived changes in communication abilities, confidence, and psychosocial well-being. Methods PwPPA participated in a 5-week, tailored telerehabilitation program (Lexical Retrieval Cascade Treatment for logopenic PPA/semantic PPA; Video-Implemented Script Training for nonfluent/agrammatic PPA). Post-treatment questionnaires were developed to collect the opinions of PwPPA and their carers regarding the SLT. The questionnaires included 22 closed-ended Likert-scale items and two open-ended questions for each group. Quantitative data were analyzed for frequency and consistency between PwPPA and carers, while qualitative responses underwent reflexive thematic analysis. Twenty-five PwPPA and 24 carers completed the questionnaires. Results Quantitative findings showed consistent perceptions between PwPPA and carers, with approximately 30% reporting improvements in communication confidence, speaking ability, and stress. Thematic analysis revealed four shared themes: reduction in negative emotions/increased self-efficacy, proactivity, acquisition of compensatory strategies, and the importance of the treatment setting and patient–clinician relationship. Additional themes included enhanced communicative effectiveness for PwPPA and increased awareness and improved interpersonal relationships for carers. Participants emphasized the benefits of individualized, supportive therapy delivered in a comfortable environment, including via telerehabilitation. Conclusion Our study highlights the positive influence of SLT on both communication and psychosocial outcomes in PwPPA and their carers. Integrating subjective experiences with quantitative measures underscores the importance of person-centered, holistic interventions that address linguistic, emotional, and social dimensions, supporting everyday communication and quality of life.
- Open Access
Rehabilitation with and without Robot and Allied Digital Technologies (RADTs) in stroke patients: a study protocol for a multicentre Randomised Controlled Trial on the effectiveness, acceptability, usability, and economic-organizational sustainability of RADTs from subacute to chronic phase (STROKEFIT4)
Introduction Rehabilitation after stroke often employs Robots and Allied Digital Technologies (RADTs). However, evidence of their effectiveness remains inconclusive due to study heterogeneity and limited sample sizes. Here, we describe a protocol for a multicentre randomized controlled pragmatic trial aimed at comprehensively and accurately assessing the effectiveness and sustainability of RADT-mediated rehabilitation, compared to traditional rehabilitation. Methods and analysis This is a pragmatic multicentre, multimodal, randomised, controlled, parallel-group (1:1) interventional study with blinded assessors. The trial will recruit 596 adult post-stroke patients in the subacute phase (less than 6 months post-stroke). Patients will be recruited from thirteen rehabilitation centres participating in a national research initiative, encompassing both outpatient and inpatient clinical settings. Participants will be randomized into either the experimental group, or the control group. The experimental group will receive rehabilitation using RADTs within a new organizational model, where two physical therapists supervise four to six patients; patients will undergo a comprehensive rehabilitation treatment, targeting the following domains: a) upper limb sensorimotor abilities; b) lower limb sensorimotor abilities and gait; c) balance; d) cognitive abilities. In the control group, patients will undergo individual traditional rehabilitation, maintaining a 1:1 patient-to-therapist ratio, targeting the same domains. Patients will undergo a total of 25 sessions, each lasting 45 minutes, with a frequency of 5 times a week, for inpatients; and 3 times a week, for outpatients. The primary endpoint is to demonstrate non-inferiority in the recovery of the activities of daily living as measured by the modified Barthel Index. If non-inferiority is established, the study will then evaluate the superiority of RADTs in the recovery of the activities of daily living. Secondary endpoints include improvements in upper and lower limb function, balance, cognitive function, and, according to the ICF, in the body functions, activities, and participation domains. Additional analyses will cover neurophysiological assessments of neural plasticity, as well as biochemical, and genetic evaluations. Upper limb dexterity and gait recovery rates during treatment will be monitored. The study will also evaluate daily activities and quality of life during a six-month follow-up period post-treatment. Acceptability and usability of integrated RADTs-based rehabilitation for patients, families, and healthcare providers, along with economic and organizational sustainability for patients, payers, and society, will also be assessed. Outcomes will be measured and analysed by blinded assessors. Ethics and dissemination This study was reviewed and approved by National Ethics Committee for clinical trials of Public Research Bodies (EPR) and other National Public Institutions (CEN). The results will be disseminated through scientific articles in peer-reviewed journals and presentations at both national and international conferences. Trial registration number NCT06547827 • The effectiveness of robotics and allied technologies will be evaluated using a novel approach involving a multimodal intervention. This approach addresses all impaired functions to holistically enhance activities of daily living, which represent the patient’s most important needs. • In addition to clinical scales, neurophysiological and biochemical data will be considered for a deeper understanding of the mechanisms underlying motor recovery. • Detailed patient profiling will enable the creation of predictive models to identify subjects who may respond better to treatment integrated with robotics and allied technologies. • The economic analysis will allow us to assess the sustainability of a new organizational model based on the use of robotics and allied technologies, where two physiotherapists supervise a group of patients simultaneously. • A study limitation is the use of different technologies across research centres. However, this reflects real-world conditions. To address the inevitable variability, we clearly defined the functional domains for treatment with robotic or technological systems, focusing on the lower limbs, balance, upper limb segments, and cognitive functions. Moreover, to manage other possible sources of variability due to the number of centres involved, a consensus was reached about clear protocols for clinical evaluation and therapy administration to be shared in clinical practice by all the participating centres.
Open AccessRehabilitation with and without Robot and Allied Digital Technologies (RADTs) in stroke patients: a study protocol for a multicentre Randomised Controlled Trial on the effectiveness, acceptability, usability, and economic-organizational sustainability of RADTs from subacute to chronic phase (STROKEFIT4)
Introduction Rehabilitation after stroke often employs Robots and Allied Digital Technologies (RADTs). However, evidence of their effectiveness remains inconclusive due to study heterogeneity and limited sample sizes. Here, we describe a protocol for a multicentre randomized controlled pragmatic trial aimed at comprehensively and accurately assessing the effectiveness and sustainability of RADT-mediated rehabilitation, compared to traditional rehabilitation. Methods and analysis This is a pragmatic multicentre, multimodal, randomised, controlled, parallel-group (1:1) interventional study with blinded assessors. The trial will recruit 596 adult post-stroke patients in the subacute phase (less than 6 months post-stroke). Patients will be recruited from thirteen rehabilitation centres participating in a national research initiative, encompassing both outpatient and inpatient clinical settings. Participants will be randomized into either the experimental group, or the control group. The experimental group will receive rehabilitation using RADTs within a new organizational model, where two physical therapists supervise four to six patients; patients will undergo a comprehensive rehabilitation treatment, targeting the following domains: a) upper limb sensorimotor abilities; b) lower limb sensorimotor abilities and gait; c) balance; d) cognitive abilities. In the control group, patients will undergo individual traditional rehabilitation, maintaining a 1:1 patient-to-therapist ratio, targeting the same domains. Patients will undergo a total of 25 sessions, each lasting 45 minutes, with a frequency of 5 times a week, for inpatients; and 3 times a week, for outpatients. The primary endpoint is to demonstrate non-inferiority in the recovery of the activities of daily living as measured by the modified Barthel Index. If non-inferiority is established, the study will then evaluate the superiority of RADTs in the recovery of the activities of daily living. Secondary endpoints include improvements in upper and lower limb function, balance, cognitive function, and, according to the ICF, in the body functions, activities, and participation domains. Additional analyses will cover neurophysiological assessments of neural plasticity, as well as biochemical, and genetic evaluations. Upper limb dexterity and gait recovery rates during treatment will be monitored. The study will also evaluate daily activities and quality of life during a six-month follow-up period post-treatment. Acceptability and usability of integrated RADTs-based rehabilitation for patients, families, and healthcare providers, along with economic and organizational sustainability for patients, payers, and society, will also be assessed. Outcomes will be measured and analysed by blinded assessors. Ethics and dissemination This study was reviewed and approved by National Ethics Committee for clinical trials of Public Research Bodies (EPR) and other National Public Institutions (CEN). The results will be disseminated through scientific articles in peer-reviewed journals and presentations at both national and international conferences. Trial registration number NCT06547827 • The effectiveness of robotics and allied technologies will be evaluated using a novel approach involving a multimodal intervention. This approach addresses all impaired functions to holistically enhance activities of daily living, which represent the patient’s most important needs. • In addition to clinical scales, neurophysiological and biochemical data will be considered for a deeper understanding of the mechanisms underlying motor recovery. • Detailed patient profiling will enable the creation of predictive models to identify subjects who may respond better to treatment integrated with robotics and allied technologies. • The economic analysis will allow us to assess the sustainability of a new organizational model based on the use of robotics and allied technologies, where two physiotherapists supervise a group of patients simultaneously. • A study limitation is the use of different technologies across research centres. However, this reflects real-world conditions. To address the inevitable variability, we clearly defined the functional domains for treatment with robotic or technological systems, focusing on the lower limbs, balance, upper limb segments, and cognitive functions. Moreover, to manage other possible sources of variability due to the number of centres involved, a consensus was reached about clear protocols for clinical evaluation and therapy administration to be shared in clinical practice by all the participating centres.
- Open Access
- 30 September 2021
- Published by International Society for Neuroregulation and Research (ISNR) in NeuroRegulation
- Vol. 8 (3) , 149
Intensive Neurofeedback-based Training to Improve Impaired Attention and Executive Functions Secondary to Resection of Tuberculum Sellae Meningioma: A Case Study
Introduction. The present study aimed to evaluate the effectiveness of neurofeedback (NFB) for the treatment of acquired cognitive impairment after brain tumor surgery. Methods. The patient was a 49-year-old bilingual African woman who underwent surgical craniotomy after a tuberculum sellae meningioma was diagnosed. Cognitive deficits were evident following post-surgical recovery, and therefore intensive NFB training consisting of 15 sessions was carried out over a period of three weeks. Full neuropsychological testing and quantitative EEG analysis were performed before and after the training for outcome measurements. Results. The treatment resulted in improved attention and executive functions; specifically sustained, focused, and divided attentional abilities; cognitive flexibility, access to the lexical vocabulary, and a better processing speed. Analysis of the qEEG revealed an increased alpha peak frequency value and reduced delta/alpha ratio in frontal areas. The EEG examination revealed interhemispheric asymmetry after treatment. Conclusion. These findings suggest that a delta/alpha decrease might account for some clinical effects on cognitive abilities seen in a brain tumor resection survivor, reducing cognitive symptoms that can have a significant impact on daily life functions. Future studies on larger patients’ samples should clarify the feasibility of NFB protocols for patients with brain tumors.
- 30 September 2021
- Published by International Society for Neuroregulation and Research (ISNR) in NeuroRegulation
- Vol. 8 (3) , 149
Open AccessIntensive Neurofeedback-based Training to Improve Impaired Attention and Executive Functions Secondary to Resection of Tuberculum Sellae Meningioma: A Case Study
Introduction. The present study aimed to evaluate the effectiveness of neurofeedback (NFB) for the treatment of acquired cognitive impairment after brain tumor surgery. Methods. The patient was a 49-year-old bilingual African woman who underwent surgical craniotomy after a tuberculum sellae meningioma was diagnosed. Cognitive deficits were evident following post-surgical recovery, and therefore intensive NFB training consisting of 15 sessions was carried out over a period of three weeks. Full neuropsychological testing and quantitative EEG analysis were performed before and after the training for outcome measurements. Results. The treatment resulted in improved attention and executive functions; specifically sustained, focused, and divided attentional abilities; cognitive flexibility, access to the lexical vocabulary, and a better processing speed. Analysis of the qEEG revealed an increased alpha peak frequency value and reduced delta/alpha ratio in frontal areas. The EEG examination revealed interhemispheric asymmetry after treatment. Conclusion. These findings suggest that a delta/alpha decrease might account for some clinical effects on cognitive abilities seen in a brain tumor resection survivor, reducing cognitive symptoms that can have a significant impact on daily life functions. Future studies on larger patients’ samples should clarify the feasibility of NFB protocols for patients with brain tumors.
- 21 October 2019
- Published by Springer Nature in The Cerebellum
- Vol. 19 (1) , 40-47
The Relationships Between Ataxia and Cognition in Spinocerebellar Ataxia Type 2
The clinical spectrum of spinocerebellar ataxia type 2 includes motor manifestations and cognitive disturbances in executive functions, memory, and visuoconstructive skills. The relationships between severity of motor disturbances and altered cognition are poorly known. In this study, we assessed patients with spinocerebellar ataxia type 2 and age- and sex-matched healthy control subjects by a test battery including the Mini-mental State Examination, the Wisconsin Card Sorting test, and the Wechsler Memory Scale-Revised. The correlation between severity of motor ataxia (as assessed by a validated and widely used severity scale, the SARA scale, and by an objective automated computerized system of gait analysis) and altered cognition was then evaluated by Spearman correlation analysis. Patients performed worse than healthy controls in almost all administered neuropsychological tests. Nevertheless, only global intellectual abilities and executive functions significantly correlated with the overall severity of ataxia as assessed by the SARA scale, and impaired executive functions alone correlated with performance on several spatio-temporal gait analysis parameters. Our findings would probably suggest a prominent influence of executive functions on motor abilities in patients with spinocerebellar ataxia type 2 and raise the possibility that cognitive pharmaceutical or rehabilitative interventions may be of benefit in the management of motor problems in these patients.
- 21 October 2019
- Published by Springer Nature in The Cerebellum
- Vol. 19 (1) , 40-47
The Relationships Between Ataxia and Cognition in Spinocerebellar Ataxia Type 2
The clinical spectrum of spinocerebellar ataxia type 2 includes motor manifestations and cognitive disturbances in executive functions, memory, and visuoconstructive skills. The relationships between severity of motor disturbances and altered cognition are poorly known. In this study, we assessed patients with spinocerebellar ataxia type 2 and age- and sex-matched healthy control subjects by a test battery including the Mini-mental State Examination, the Wisconsin Card Sorting test, and the Wechsler Memory Scale-Revised. The correlation between severity of motor ataxia (as assessed by a validated and widely used severity scale, the SARA scale, and by an objective automated computerized system of gait analysis) and altered cognition was then evaluated by Spearman correlation analysis. Patients performed worse than healthy controls in almost all administered neuropsychological tests. Nevertheless, only global intellectual abilities and executive functions significantly correlated with the overall severity of ataxia as assessed by the SARA scale, and impaired executive functions alone correlated with performance on several spatio-temporal gait analysis parameters. Our findings would probably suggest a prominent influence of executive functions on motor abilities in patients with spinocerebellar ataxia type 2 and raise the possibility that cognitive pharmaceutical or rehabilitative interventions may be of benefit in the management of motor problems in these patients.
- Open Access
Botulinum Toxin Type A and Physiotherapy in Spasticity of the Lower Limbs Due to Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease (unknown pathogenesis) of the central nervous system that causes death within 1–5 years. Clinically, flabby paralysis, areflexia, muscular atrophy, and muscle fasciculations, signs of II motor neuron damage, appear. Sometimes, clinical manifestations of damage of the I motor neuron come out in lower limbs; spastic paralysis, iperflexia, and clonus emerge, and they impair deambulation and management of activities of daily living, such as personal hygiene or dressing. Thus, the first therapeutic approach in these patients involves antispasmodic drugs orally followed by botulinum toxin type A injection (BTX-A). In this study, we study the efficacy of BTX-A and physiotherapy in lower limb spasticity due to ALS and no response to treatment with oral antispastic drugs. We evaluated 15 patients (10 male and five female), with a mean age of 48.06 ± 5.2 with spasticity of adductor magnus (AM), at baseline (T0, before BTX-A treatment) and in the following three follow-up visits (T1 30 days, T2 60 days, and T3 90 days after infiltration). We evaluated myometric measure of muscle tone, the Modified Ashworth Scale of AM, Barthel Index, Adductor Tone Rating Scale, and Hygiene Score. The study was conducted between November 2018 and April 2019. We treated AM with incobotulinum toxin type A (Xeomin®, Merz). Spasticity (myometric measurement, Adductor Tone Rating Scale, and Modified Ashworth Scale) and clinical (Barthel Index and Hygiene Score) improvements were obtained for 90 days after injection (p < 0.05). Our study shows the possibility of using BTX-A in the treatment of spasticity in patients with ALS and no response to oral antispastic drugs, with no side effects. The limitation of the study is the small number of patients and the limited time of observation; therefore, it is important to increase both the number of patients and the observation time in future studies.
Open AccessBotulinum Toxin Type A and Physiotherapy in Spasticity of the Lower Limbs Due to Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease (unknown pathogenesis) of the central nervous system that causes death within 1–5 years. Clinically, flabby paralysis, areflexia, muscular atrophy, and muscle fasciculations, signs of II motor neuron damage, appear. Sometimes, clinical manifestations of damage of the I motor neuron come out in lower limbs; spastic paralysis, iperflexia, and clonus emerge, and they impair deambulation and management of activities of daily living, such as personal hygiene or dressing. Thus, the first therapeutic approach in these patients involves antispasmodic drugs orally followed by botulinum toxin type A injection (BTX-A). In this study, we study the efficacy of BTX-A and physiotherapy in lower limb spasticity due to ALS and no response to treatment with oral antispastic drugs. We evaluated 15 patients (10 male and five female), with a mean age of 48.06 ± 5.2 with spasticity of adductor magnus (AM), at baseline (T0, before BTX-A treatment) and in the following three follow-up visits (T1 30 days, T2 60 days, and T3 90 days after infiltration). We evaluated myometric measure of muscle tone, the Modified Ashworth Scale of AM, Barthel Index, Adductor Tone Rating Scale, and Hygiene Score. The study was conducted between November 2018 and April 2019. We treated AM with incobotulinum toxin type A (Xeomin®, Merz). Spasticity (myometric measurement, Adductor Tone Rating Scale, and Modified Ashworth Scale) and clinical (Barthel Index and Hygiene Score) improvements were obtained for 90 days after injection (p < 0.05). Our study shows the possibility of using BTX-A in the treatment of spasticity in patients with ALS and no response to oral antispastic drugs, with no side effects. The limitation of the study is the small number of patients and the limited time of observation; therefore, it is important to increase both the number of patients and the observation time in future studies.
- 12 June 2018
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 18 (4) , 397-400
Efficacy and Non Invasive Treatment of Sialorrhea in the Goldenhar Syndrome
Background and Objective: Goldenhar syndrome (ocular-auricular-vertebral syndrome), a rare congenital condition arising from defects in the first and second brachial arches, consists in clinical variety of features ranging from facial abnormalities, ear-eye abnormalities, vertebral defects and congenital heart problems and severe obstructive sleep apnea. Due to craniofacial abnormalities, patients presents mechanical obstructive phenomena and sialorrhea that cause prone position, language's fastening, use of nasopharyngeal cannulas and tracheal intubation. Methods: In this article, we report a case of a 16 years old child affected by Goldenhar syndrome and sialorrhea to demonstrate improvement of the daily patient management, through inoculations of botulinum toxin type A. Due to severe sialorrhea which caused tracheobronchial daily aspirations, the caregivers used an external aspirators. Results: In the first infiltration (August 2016) the parotid and submandibular glands bilaterally were inoculated with incobotulinum toxin type A (Xeomin((R)), Merz Pharma) with dosages of 5 UI for each of them, for a total of 20 UI without clinical efficacy (no quantitative and qualitative saliva reducing during 3 months). In the second (November 2016) and third (February 2017) infiltrations each parotid and each submandibular glands were injected with a (dosage of 7 UI and 5 UI respectively (total of 24 UI of incobotulinumtoxin A) with important clinical results (saliva production and tracheo-bronchial aspirations reduced). Conclusion: Therefore, botulinum toxin type A could be a good and non invasive treatment of sialorrhea in Goldenhar syndrome to improve oral hygiene and daily patient management.
- 12 June 2018
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 18 (4) , 397-400
Efficacy and Non Invasive Treatment of Sialorrhea in the Goldenhar Syndrome
Background and Objective: Goldenhar syndrome (ocular-auricular-vertebral syndrome), a rare congenital condition arising from defects in the first and second brachial arches, consists in clinical variety of features ranging from facial abnormalities, ear-eye abnormalities, vertebral defects and congenital heart problems and severe obstructive sleep apnea. Due to craniofacial abnormalities, patients presents mechanical obstructive phenomena and sialorrhea that cause prone position, language's fastening, use of nasopharyngeal cannulas and tracheal intubation. Methods: In this article, we report a case of a 16 years old child affected by Goldenhar syndrome and sialorrhea to demonstrate improvement of the daily patient management, through inoculations of botulinum toxin type A. Due to severe sialorrhea which caused tracheobronchial daily aspirations, the caregivers used an external aspirators. Results: In the first infiltration (August 2016) the parotid and submandibular glands bilaterally were inoculated with incobotulinum toxin type A (Xeomin((R)), Merz Pharma) with dosages of 5 UI for each of them, for a total of 20 UI without clinical efficacy (no quantitative and qualitative saliva reducing during 3 months). In the second (November 2016) and third (February 2017) infiltrations each parotid and each submandibular glands were injected with a (dosage of 7 UI and 5 UI respectively (total of 24 UI of incobotulinumtoxin A) with important clinical results (saliva production and tracheo-bronchial aspirations reduced). Conclusion: Therefore, botulinum toxin type A could be a good and non invasive treatment of sialorrhea in Goldenhar syndrome to improve oral hygiene and daily patient management.
- Open Access
“Appropriate Treatment” and Therapeutic Window in Spasticity Treatment with IncobotulinumtoxinA: From 100 to 1000 Units
Many neurological diseases (ischemic and hemorrhagic stroke, multiple sclerosis, infant cerebral palsy, spinal cord injuries, traumatic brain injury, and other cerebrovascular disorders) may cause muscle spasticity. Different therapeutic strategies have been proposed for the treatment of spasticity. One of the major treatments for tone modulation is botulinum toxin type A (BTX-A), performed in addition to other rehabilitation strategies based on individualized multidisciplinary programs aimed at achieving certain goals for each patient. Therapeutic plans must be precisely defined as they must balance the reduction of spastic hypertonia and retention of residual motor function. To perform and optimize the treatment, an accurate clinical and instrumental evaluation of spasticity is needed to determine how this symptom is invalidating and to choose the best doses, muscles and times of injection in each patient. We introduce an “appropriate treatment” and no “standard or high dosage treatment” concept based on our retrospective observational study on 120 patients lasting two years, according to the larger Therapeutic Index and Therapeutic Window of Incobotulinumtoxin A doses from 100 to 1000 units. We studied the efficiency and safety of this drug considering the clinical spasticity significance for specialist physicians and patients.
Open Access“Appropriate Treatment” and Therapeutic Window in Spasticity Treatment with IncobotulinumtoxinA: From 100 to 1000 Units
Many neurological diseases (ischemic and hemorrhagic stroke, multiple sclerosis, infant cerebral palsy, spinal cord injuries, traumatic brain injury, and other cerebrovascular disorders) may cause muscle spasticity. Different therapeutic strategies have been proposed for the treatment of spasticity. One of the major treatments for tone modulation is botulinum toxin type A (BTX-A), performed in addition to other rehabilitation strategies based on individualized multidisciplinary programs aimed at achieving certain goals for each patient. Therapeutic plans must be precisely defined as they must balance the reduction of spastic hypertonia and retention of residual motor function. To perform and optimize the treatment, an accurate clinical and instrumental evaluation of spasticity is needed to determine how this symptom is invalidating and to choose the best doses, muscles and times of injection in each patient. We introduce an “appropriate treatment” and no “standard or high dosage treatment” concept based on our retrospective observational study on 120 patients lasting two years, according to the larger Therapeutic Index and Therapeutic Window of Incobotulinumtoxin A doses from 100 to 1000 units. We studied the efficiency and safety of this drug considering the clinical spasticity significance for specialist physicians and patients.
- 1 February 2017
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 96 (2) , S80-S82
People with Spinal Cord Injury in Italy
- 1 February 2017
- Published by Wolters Kluwer Health in American Journal of Physical Medicine & Rehabilitation
- Vol. 96 (2) , S80-S82
People with Spinal Cord Injury in Italy